Search

Your search keyword '"LASOTA, MAGDALENA"' showing total 8 results
Start Over Author "LASOTA, MAGDALENA" Topic survival
8 results on '"LASOTA, MAGDALENA"'

1. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study.

Author

Bielska-Lasota, Magdalena, Rossi, Silvia, Krzyżak, Michalina, Haelens, Annemie, Domenic, Augius, De Angelis, Roberta, Maciejczyk, Adam, Rodríguez-Barranco, Miguel, Zadnik, Vesna, Minicozzi, Pamela, EUROCARE-5 Working Group, Hackl, M., Ihle, P., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Cukelj, P., and Dušek, L.

Subjects
*CERVICAL cancer, *CERVIX uteri diseases, *TUMOR classification, *MEDICAL care, *OLDER women, EUROPEAN Union membership
Abstract

Purpose: With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across five European regions, considering stage at diagnosis (local, regional and metastatic), morphology (mainly squamous versus glandular tumours) and patients' age.Methods: We analysed 101,714 CC women diagnosed in 2000-2007 and followed-up to December 2008. Age-standardised 5-year relative survival (RS) and the excess risks of cancer death in the 5 years after diagnosis were computed.Results: EE women were older and less commonly diagnosed with glandular tumours. Proportions of local stage cancers were similar across Europe, while morphology- and stage-specific RS (especially for non-metastatic disease) were lower in Eastern Europe. Adjusting for age and morphology, excess risk of local stage CC death for EE patients remained higher than that for other European women.Conclusion: Stage, age and morphology alone do not explain worse survival in Eastern Europe: less effective care may play a role, probably partly due to fewer or inadequate resources being allocated to health care in this area, compared to the rest of Europe. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Author

Allemani, Claudia, Weir, Hannah K., Carreira, Helena, Harewood, Rhea, Spika, Devon, Wang, Xiao-Si, Bannon, Finian, Ahn, Jane V, Johnson, Christopher J., Bonaventure, Audrey, Marcos-Gragera, Rafael, Stiller, Charles, Azevedo E Silva, Gulnar, Chen, Wan-Qing, Ogunbiyi, Olufemi J., Rachet, Bernard, Soeberg, Matthew J, You, Hui, Matsuda, Tomohiro, Bielska-Lasota, Magdalena, Storm, Hans, Tucker, Thomas C., Coleman, Michel, P, CONCORD Working Group (Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, Sh, Stefan, Cd, El Mistiri MM, Bayo, S, Malle, B, Manraj, Ss, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, Oj, Bradshaw, D, Somdyala, Ni, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, Ms, Laura, E, Pugh, Fv, Torrent, Me, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, Pl, Diumenjo, Mc, Laspada, Wd, Green, Ma, Lanza, Mf, Ibañez, Sg, Lima, Ca, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza PC, Del Pino, K, Laporte, C, Curado, Mp, de Oliveira JC, Veneziano, Cl, Veneziano, Db, Alexandre, Ts, Verdugo, As, Koifman, S, e Silva G, Azevedo, Galaz, Jc, Moya, Ja, Herrmann, Da, Jofre, Am, Uribe, Cj, Bravo, Le, Lopez Guarnizo, G, Jurado, Dm, Yepes, Mc, Galán, Yh, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, Cr, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, Aj, Woods, Rr, Noonan, G, Turner, D, Kumar, E, Zhang, B, Mccrate, Fr, Ryan, S, Hannah, H, Dewar, Ra, Macintyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, De, Vriends, Ka, Bertrand, C, Louchini, R, Robb, Ki, Stuart-Panko, H, Demers, S, Wright, S, George, J, Shen, X, Brockhouse, Jt, O'Brien, Dk, Almon, L, Young, Jl, Bates, J, Rycroft, R, Mueller, L, Phillips, C, Ryan, H, Walrath, J, Schwartz, A, Vigneau, F, Mackinnon, Ja, Wohler, B, Bayakly, R, Ward, Kc, Davidson-Allen, K, Glaser, S, West, D, Green, Md, Hernandez, By, Johnson, Cj, Lynch, Cf, Mckeen, Km, Huang, B, Tucker, Tc, Deapen, D, Liu, L, Hsieh, Mc, Wu, Xc, Stern, K, Gershman, St, Knowlton, Rc, Copeland, G, Spivak, G, Rogers, Db, Lemons, D, Williamson, Ll, Hood, M, Jerry, H, Hosain, Gm, Rees, Jr, Pawlish, Ks, Stroup, A, Key, C, Wiggins, C, Kahn, Ar, Schymura, Mj, Leung, G, Rao, C, Giljahn, L, Warther, B, Pate, A, Patil, M, Shipley, Dk, Esterly, M, Otto, Rd, Fulton, Jp, Rousseau, Dl, Janes, Ta, Schwartz, Sm, Bolick, Sw, Hurley, Dm, Tenney, Ra, Whiteside, Ma, Hakenewerth, A, Williams, Ma, Herget, K, Sweeney, C, Martin, J, Wang, S, Harrelson, Mg, Keitheri Cheteri MB, Hudson, Ag, Borchers, R, Stephenson, L, Espinoza, Jr, Weir, Hk, Edwards, Bk, Wang, N, Yang, L, Chen, Js, Song, Gh, Gu, Xp, Zhang, P, Ge, Hm, Zhao, Dl, Zhang, Jh, Zhu, Fd, Tang, Jg, Shen, Y, Wang, J, Li, Ql, Yang, Sp, Dong, Jm, Li, Ww, Cheng, Lp, Chen, Jg, Huang, Qh, Huang, Sq, Guo, Gp, Wei, K, Chen, Wq, Zeng, H, Demetriou, Aw, Pavlou, P, Mang, Wk, Ngan, Kc, Kataki, Ac, Krishnatreya, M, Jayalekshmi, Pa, Sebastian, P, Sapkota, Sd, Verma, Y, Nandakumar, A, Suzanna, E, Keinan-Boker, L, Silverman, Bg, Ito, H, Hattori, M, Sugiyama, H, Utada, M, Katayama, K, Natsui, S, Matsuda, T, Nishino, Y, Koike, T, Ioka, A, Nakata, K, Kosa, K, Oki, I, Shibata, A, Nimri, O, Ab Manan, A, Bhoo Pathy, N, Ochir, C, Tuvshingerel, S, Al Khater AM, Al-Eid, H, Jung, Kw, Won, Yj, Park, S, Chiang, Cj, Lai, Ms, Suwanrungruang, K, Wiangnon, S, Daoprasert, K, Pongnikorn, D, Geater, Sl, Sriplung, H, Eser, S, Yakut, Ci, Hackl, M, Zielonke, N, Mühlböck, H, Oberaigner, W, Piñeros, M, Zborovskaya, Aa, Henau, K, Van Eycken, L, Dimitrova, N, Valerianova, Z, Šekerija, M, Znaor, A, Zvolský, M, Engholm, G, Storm, H, Aareleid, T, Mägi, M, Malila, N, Seppä, K, Velten, M, Cornet, E, Troussard, X, Bouvier, Am, Faivre, J, Guizard, Av, Bouvier, V, Launoy, G, Arveux, P, Maynadié, M, Mounier, M, Woronoff, As, Daoulas, M, Clavel, J, Le Guyader-Peyrou, S, Monnereau, A, Trétarre, B, Colonna, M, Delacour-Billon, S, Molinié, F, Bara, S, Degré, D, Ganry, O, Lapôtre-Ledoux, B, Grosclaude, P, Lutz, Jm, Belot, A, Estève, J, Forman, D, Sassi, F, Stabenow, R, Eberle, A, Nennecke, A, Kieschke, J, Sirri, E, Kajueter, H, Emrich, K, Zeissig, Sr, Holleczek, B, Eisemann, N, Katalinic, A, Brenner, H, Asquez, Ra, Kumar, V, Ólafsdóttir, Ej, Tryggvadóttir, L, Comber, H, Walsh, Pm, Sundseth, H, Dal Cappello, T, Mazzoleni, G, Giacomin, A, Castaing, M, Sciacca, S, Sutera, A, Corti, M, Gola, G, Ferretti, S, Serraino, D, Zucchetto, A, Lillini, R, Vercelli, M, Busco, S, Pannozzo, F, Vitarelli, S, Ricci, P, Pascucci, V, Autelitano, M, Cirilli, C, Federico, M, Fusco, M, Vitale, Mf, Usala, M, Cusimano, R, Vitale, F, Michiara, M, Sgargi, P, Sacerdote, C, Tumino, R, Mangone, L, Falcini, F, Cremone, L, Budroni, M, Cesaraccio, R, Madeddu, A, Tisano, F, Maspero, S, Tessandori, R, Candela, G, Scuderi, T, Piffer, S, Rosso, S, Zanetti, R, Caldarella, A, Crocetti, E, La Rosa, F, Stracci, F, Contiero, P, Tagliabue, G, Zambon, P, Baili, P, Berrino, F, Gatta, G, Sant, M, Capocaccia, R, De Angelis, R, Verdecchia, A, Liepina, E, Maurina, A, Smailyte, G, Agius, D, Calleja, N, Siesling, S, Laronningen, S, Møller, B, Dyzmann-Sroka, A, Trojanowski, M, Góźdż, S, Mężyk, R, Gądalska-Lampart, M, Radziszewska, Au, Didkowska, J, Wojciechowska, U, Błaszczyk, J, Kępska, K, Bielska-Lasota, M, Forjaz, G, Rego, Ra, Bastos, J, Antunes, L, Bento, Mj, da Costa Miranda AM, Mayer-da-Silva, A, Coza, D, Todescu, Ai, Krasilnikov, A, Valkov, M, Adamcik, J, Safaei Diba, C, Primic Žakelj, M, Žagar, T, Stare, J, Almar, E, Mateos, A, Argüelles, Mv, Quirós, Jr, Bidaurrazaga, J, Larrañaga, N, Díaz García JM, Marcos, Ai, Marcos-Gragera, R, Vilardell Gil ML, Molina, E, Sánchez, Mj, Ramos Montserrat, M, Chirlaque, Md, Navarro, C, Ardanaz, E, Felipe Garcia, S, Peris-Bonet, R, Galceran, J, Khan, S, Lambe, M, Camey, B, Bouchardy, C, Usel, M, Ess, Sm, Hermann, C, Levi, Fg, Maspoli-Conconi, M, Kuehni, Ce, Mitter, Vr, Bordoni, A, Spitale, A, Chiolero, A, Konzelmann, I, Dehler, Si, Laue, Ri, Meechan, D, Poole, J, Greenberg, D, Rashbass, J, Davies, E, Linklater, K, Morris, E, Moran, T, Bannon, F, Gavin, A, Black, Rj, Brewster, Dh, Roche, M, Mcphail, S, Verne, J, Murphy, M, Stiller, C, Huws, Dw, White, C, Lawrence, G, Brook, C, Wilkinson, J, Finan, P, Ahn, Jv, Allemani, C, Bonaventure, A, Carreira, H, Coleman, Mp, Harewood, R, Rachet, B, Sanz, N, Spika, D, Wang, Xs, Stephens, R, Butler, J, Peake, M, Chalker, E, Newman, L, Baker, D, Soeberg, Mj, Scott, C, Stokes, Bc, Venn, A, Farrugia, H, Giles, Gg, Threlfall, T, Currow, D, You, H, Lewis, C, Miles, SA), Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy, Bouchardy Magnin, Christine, Usel, Massimo, Allemani, C, Weir, H, Carreira, H, Harewood, R, Spika, D, Wang, X, Bannon, F, Ahn, J, Johnson, C, Bonaventure, A, Marcos Gragera, R, Stiller, C, Silva, G, Chen, W, Ogunbiyi, O, Rachet, B, Soeberg, M, You, H, Matsuda, T, Bielska Lasota, M, Storm, H, Tucker, T, Coleman, M, Vitale, F, University of Zurich, and Coleman, Michel P

Subjects
Male, europe 1999-2007, Pathology, Càncer -- Estadístiques, Survival, [SDV]Life Sciences [q-bio], 2700 General Medicine, Global Health, Settore MED/42 - Igiene Generale E Applicata, Neoplasms, 80 and over, Global health, Registries, Stomach cancer, Child, cancer survival, Breast-cancer, ComputingMilieux_MISCELLANEOUS, cancer registry, worldwide, Cervical cancer, Aged, 80 and over, education.field_of_study, childhood-cancer, Medicine (all), 1. No poverty, General Medicine, population-based registries, surveillance, Middle Aged, 3. Good health, ovarian-cancer, Child, Preschool, population-based registrie, Female, net survival, Neoplasms/mortality, rectal-cancer, nordic countries, data quality, care, stage, Adult, medicine.medical_specialty, Adolescent, Population, Socio-culturale, 610 Medicine & health, Age Distribution, Aged, Humans, Infant, Infant, Newborn, Sex Distribution, Survival Analysis, Young Adult, Article, Breast cancer, SDG 3 - Good Health and Well-being, cancer registries, medicine, Preschool, education, Supervivència, Survival analysis, ddc:613, Cancer -- Statistics, business.industry, Cancer, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), Newborn, medicine.disease, Cancer registry, business, Demography
Abstract

Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the eff ectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major defi ciencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide diff erences that are likely to be attributable to diff erences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems This work was funded by the Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK (C1336/A16148), US Centers for Disease Control and Prevention (CDC; 12FED03123, ACO12036), Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky (3049024672-12-568)

Published
2014
Full Text
View/download PDF

3. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study

Author

Berrino , Franco, De Angelis , Roberta, Sant , Milena, Rosso , Stefano, Bielska-Lasota , Magdalena, Lasota , Magdalena B, Coebergh , Jan W, Santaquilani , Mariano, Renseigné , Non, Danzon , Arlette, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Survival, MESH: Registries, MESH : Aged, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, MESH: Health Surveys, 0302 clinical medicine, Survival data, Neoplasms, Epidemiology, MESH : Socioeconomic Factors, MESH: Neoplasms, 030212 general & internal medicine, Registries, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Relative survival, Health Care Costs, Middle Aged, MESH : Adult, major cancers, all cancers combined, European adults, 3. Good health, Europe, Oncology, MESH: Survival Analysis, 030220 oncology & carcinogenesis, MESH : Resource Allocation, MESH : Health Care Costs, Adult, MESH: Socioeconomic Factors, medicine.medical_specialty, Adolescent, Population, education, MESH : Europe, MESH : Health Surveys, MESH: Health Care Costs, [SDV.CAN]Life Sciences [q-bio]/Cancer, Resource Allocation, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Survival analysis, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Health Surveys, Survival Analysis, MESH : Neoplasms, Socioeconomic Factors, MESH: Resource Allocation, MESH: Europe, MESH : Survival Analysis, business, MESH : Registries, Demography
Abstract

International audience; BACKGROUND: EUROCARE is the largest population-based cooperative study on survival of patients with cancer. The EUROCARE project aims to regularly monitor, analyse, and explain survival trends and between-country differences in survival. This report (EUROCARE-4) presents survival data for eight selected cancer sites and for all cancers combined, diagnosed in adult (aged >/=15 years) Europeans in 1995-99 and followed up until the end of 2003. METHODS: We analysed data from 83 cancer registries in 23 European countries on 2 699 086 adult cancer cases that were diagnosed in 1995-99 and followed up to December, 2003. We calculated country-specific and mean-weighted age-adjusted 5-year relative survival for eight major cancers. Additionally, case-mix-adjusted 5-year survival for all cancers combined was calculated by countries ranked by total national expenditure on health (TNEH). Changes to survival were analysed relative to cases diagnosed in 1990-94. FINDINGS: Mean age-adjusted 5-year relative survival for colorectal (53.8% [95% CI 53.3-54.1]), lung (12.3% [12.1-12.5]), breast (78.9% [78.6-79.2]), prostate (75.7% [75.2-76.2]), and ovarian (36.3% [35.7-37.0]) cancer was highest in Nordic countries (except Denmark) and central Europe, intermediate in southern Europe, lower in the UK and Ireland, and worst in eastern Europe. Survival for melanoma (81.6% [81.0-82.3]), cancer of the testis (94.2% [93.4-95.0]), and Hodgkin's disease (80.0% [79.0-81.0]) varied little with geography. All-cancer survival correlated with TNEH for most countries. Denmark and UK had lower all-cancer survival than countries with similar TNEH; Finland had high all-cancer survival, but moderate TNEH. Survival increased and intercountry survival differences narrowed between the data for 1990-94 and 1995-99 for, notably, Hodgkin's disease (range 66.1-82.9 [IQR 72.2-78.6] vs 74.0-83.9 [78.6-81.9]), colorectal (29.4-56.7 [45.8-54.1] vs 38.8-59.7 [50.7-57.5]), and breast (61.7-82.7 [72.3-78.3] vs 69.3-87.6 [76.6-82.7]) sites. INTERPRETATION: Increases in survival and decreases in geographic differences over time, which are mainly due to improvements in health-care services in countries with poor survival, might indicate better cancer care. Wealthy countries with high TNEH generally had good cancer outcomes, but those with conspicuously worse outcomes than those with similar TNEH might not be allocating health resources efficiently.

Published
2007
Full Text
View/download PDF

4. Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade.

Author

Oberaigner, Willi, Minicozzi, Pamela, Bielska-Lasota, Magdalena, Allemani, Claudia, de Angelis, Roberta, Mangone, Lucia, and Sant, Milena

Subjects
CONFIDENCE intervals, REPORTING of diseases, OVARIAN tumors, PUBLIC health surveillance, RESEARCH funding, SURVIVAL, SECONDARY analysis, DATA analysis software, DESCRIPTIVE statistics, PROGNOSIS
Abstract

Background. Survival for ovarian cancer is the poorest of all gynaecological cancer sites. Our aim was to present the most up-to-date survival estimate for ovarian cancer by age and morphology and to answer the question whether survival for ovarian cancer improved in Europe during the 1990s. Material and methods. This analysis was performed with data from the EUROCARE database. We considered all adult women diagnosed with ovarian cancer between 1995 and 2002 and life status followed up until the end of 2003. A total of 97 691 cases were contributed by 72 European cancer registries in 24 countries. We estimated the most up-to-date relative survival for a mean of 23 661 patients followed up in 2000-2003 using the period hybrid approach and described the relative survival trends from the beginning of 1990s. Results and conclusion. Overall, the European age-standardised one-year, five-year and five-year conditional on surviving one-year relative survival were 67.2% (95% CI 66.6-67.8), 36.1% (95% CI 35.4-36.8) and 53.7% (95% CI 52.8-54.7), respectively. Five-year relative survival was 58.6% (95% CI 57.4-59.8), 37.1% (95% CI 36.1-38.1) and 20.5% (95% CI 19.1-21.9) in women aged 15-54, 55-74 and 75-99 years, respectively. The age-standardised five-year relative survival was 38.1% (95% CI 36.9-39.3) for serous tumours and 51.9% (95% CI 49.0-54.9) for mucinous cancers and the crude five-year relative survival was 85.6% (95% CI 81.2-90.0) for germ cell cancers. Overall, the age-standardised five-year relative survival increased from 32.4% (95% CI 31.7-33.2) in 1991-1993 to 36.3% (95% CI 35.5-37.0) in 2000-2003. There is a need to better understand the reasons for the wide variation in survival of ovarian cancer in Europe. Actions aiming to harmonise the protocols for therapy should contribute to narrowing the wide gap in survival and research on screening and early detection of ovarian cancer should be enforced. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

5. Trends in cervical cancer survival in Europe, 1983–1994: A population-based study

Author

Bielska-Lasota, Magdalena, Inghelmann, Riccardo, van de Poll-Franse, Lonneke, and Capocaccia, Riccardo

Subjects
*CANCER patients, *CERVICAL cancer, *ADENOCARCINOMA
Abstract

Abstract: Objective. : To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. Methods. : Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15–99 years diagnosed during 1983–1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. Results. : Overall five-year relative survival was 62%, rising by 2% during the period 1983–1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. Conclusions. : Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

6. Survival of European adolescents and young adults diagnosed with cancer in 2010–2014.

Author

Trama, Annalisa, Botta, Laura, Stiller, Charles, Visser, Otto, Cañete-Nieto, Adela, Spycher, Ben, Bielska-Lasota, Magdalena, Katalinic, Alexander, Vener, Claudia, Innos, Kaire, Marcos-Gragera, Rafael, Paapsi, Keiu, Guevara, Marcela, Demuru, Elena, Mousavi, Seyed Mohsen, Blum, Marcel, Eberle, Andrea, Ferrari, Andrea, Bernasconi, Alice, and Lasalvia, Paolo

Subjects
*TUMOR diagnosis, *SURVIVAL rate, *HEMATOLOGIC malignancies, *CANCER patients, *DESCRIPTIVE statistics, *CENTRAL nervous system, *REPORTING of diseases, *LYMPHOBLASTIC leukemia, *ADOLESCENCE, *ADULTS
Abstract

We used the comprehensive definition of AYA (age 15 to 39 years) to update 5-year relative survival (RS) estimates for AYAs in Europe and across countries and to evaluate improvements in survival over time. We used data from EUROCARE-6. We analysed 700,000 AYAs with cancer diagnosed in 2000–2013 (follow-up to 2014). We focused the analyses on the 12 most common cancers in AYA. We used period analysis to estimate 5-year RS in Europe and 5-year RS differences in 29 countries (2010–2014 period estimate) and over time (2004–06 vs. 2010–14 period estimates). 5-year RS for all AYA tumours was 84%, ranging from 70% to 90% for most of the 12 tumours analysed. The exceptions were acute lymphoblastic leukaemia, acute myeloid leukaemia, and central nervous system tumours, presenting survival of 59%, 61%, and 62%, respectively. Differences in survival were observed among European countries for all cancers, except thyroid cancers and ovarian germ-cell tumours. Survival improved over time for most cancers in the 15- to 39-year-old age group, but for fewer cancers in adolescents and 20- to 29-year-olds. This is the most comprehensive study to report the survival of 12 cancers in AYAs in 29 European countries. We showed variability in survival among countries most likely due to differences in stage at diagnosis, access to treatment, and lack of referral to expert centres. Survival has improved especially for haematological cancers. Further efforts are needed to improve survival for other cancers as well, especially in adolescents. • Tumours of adolescents and young adults can be treated effectively. • Application of paediatric protocols to AYAs with ALL improves outcomes. • We highlighted survival differences between European countries for most AYA tumours. • Survival improved over time for most cancers in the 15- to 39-year-old age group. • Survival improved over time for fewer cancers in those aged 15 to 29. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study.

Author

Sant, Milena, Chirlaque Lopez, Maria Dolores, Agresti, Roberto, Sánchez Pérez, Maria José, Holleczek, Bernd, Bielska-Lasota, Magdalena, Dimitrova, Nadya, Innos, Kaire, Katalinic, Alexander, Langseth, Hilde, Larrañaga, Nerea, Rossi, Silvia, Siesling, Sabine, and Minicozzi, Pamela

Subjects
*BREAST tumors, *CANCER patients, *REPORTING of diseases, *FEMALE reproductive organ tumors, *HEALTH services accessibility, *LONGITUDINAL method, *SURVIVAL analysis (Biometry), *SURVIVAL, *TUMORS, *WOMEN'S health, *HEALTH equity
Abstract

Background: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. Methods: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions. We used the cohort approach to estimate 5-year relative survival (RS) for adult (≥15 years) women diagnosed 2000-2007, by age, country and region; and the period approach to estimate time trends (1999-2007) in RS for breast and cervical cancers. Results: In 2000-2007, 5-year RS was 57% overall, 82% for women diagnosed with breast, 76% with corpus uteri, 62% with cervical, 38% with ovarian, 40% with vaginal and 62% with vulvar cancer. Survival was low for patients resident in Eastern Europe (34% ovary-74% breast) and Ireland and the United Kingdom [Ireland/UK] (31-79%) and high for those resident in Northern Europe (41-85%) except Denmark. Survival decreased with advancing age: markedly for women with ovarian (71% 15-44 years; 20% ≥75 years) and breast (86%; 72%) cancers. Survival for patients with breast and cervical cancers increased from 1999-2001 to 2005-2007, remarkably for those resident in countries with initially low survival. Conclusions: Despite increases over time, survival for women's cancers remained poor in Eastern Europe, likely due to advanced stage at diagnosis and/or suboptimum access to adequate care. Low survival for women living in Ireland/UK and Denmark could indicate late detection, possibly related also to referral delay. Poor survival for ovarian cancer across the continent and over time suggests the need for a major research effort to improve prognosis for this common cancer. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

8. Carcinoma of endocrine organs: Results of the RARECARE project

Author

van der Zwan, Jan Maarten, Mallone, Sandra, van Dijk, Boukje, Bielska-Lasota, Magdalena, Otter, Renée, Foschi, Roberto, Baudin, Eric, and Links, Thera P.

Subjects
*ENDOCRINE gland tumors, *SEX distribution, *SURVIVAL, *DESCRIPTIVE statistics
Abstract

Abstract: The rarity or the asymptomatic character of endocrine tumours results in a lack of epidemiological studies on their incidence and survival patterns. The aim of this study was to describe the incidence, prevalence and survival of endocrine tumours using a large database, which includes cancer patients diagnosed from 1978 to 2002, registered in 89 population-based cancer registries (CRs) with follow-up until 31st December 2003. These data give an unique overview of the burden of endocrine carcinomas in Europe. A list of tumour entities based on the third International Classification of Diseases for Oncology was provided by the project Surveillance of rare cancer in Europe (RARECARE) project. Over 33,594 cases of endocrine carcinomas were analysed in this study. Incidence rates increased with age and were highest in patients 65 years of age or older. In 2003, more than 315,000 persons in the EU (27 countries) were alive with a past diagnosis of a carcinoma of endocrine organs. The incidence of pituitary carcinoma equalled four per 1,000,000 person years and showed the strongest decline in survival with increasing age. Thyroid cancer showed the highest crude incidence rates (four per 100,000 person years) and was the only entity with a gender difference: (female-to-male ratio: 2:9). Parathyroid carcinoma was the rarest endocrine entity with two new cases per 10,000,000 person years. For adrenal carcinoma, the most remarkable observations were a higher survival for women compared to men (40% compared to 32%, respectively) and a particularly low relative survival of 24% in patients 65years of age or older. More high quality studies on rare cancers, with additional information, e.g. on stage and therapeutic approach, are needed and may be of help in partly explaining the observed variation in survival. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results